Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib: Clinical Paradigm and Molecular Mechanisms in Precision Cardiovascular Medicine

Following the neutral results of the dal-OUTCOMES trial, a genome-wide study identified the rs1967309 variant in the adenylate cyclase type 9 (ADCY9) gene on chromosome 16 as being associated with the risk of future cardiovascular events only in subjects taking dalcetrapib, a CETP (cholesterol ester...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Circ Genom Precis Med
Main Authors: Rhainds, David, Packard, Chris J., Brodeur, Mathieu R., Niesor, Eric J., Sacks, Frank M., Jukema, J. Wouter, Wright, R. Scott, Waters, David D., Heinonen, Therese, Black, Donald M., Laghrissi-Thode, Fouzia, Dubé, Marie-Pierre, Pfeffer, Marc A., Tardif, Jean-Claude
Format: Artigo
Jezik:Inglês
Izdano: Lippincott Williams & Wilkins 2021
Teme:
Review
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8284386/
https://ncbi.nlm.nih.gov/pubmed/33794646
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCGEN.121.003219
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki